Literature DB >> 32808882

LDL-Cholesterol Reduction by ANGPTL3 Inhibition in Mice Is Dependent on Endothelial Lipase.

Liya Wu1, Mangala M Soundarapandian2, Adam B Castoreno2, John S Millar1, Daniel J Rader1,3.   

Abstract

Entities:  

Keywords:  angiopoietins; cholesterol; lipoproteins; metabolism; triglycerides

Mesh：

Substances：

Year:  2020        PMID： 32808882     DOI： 10.1161/CIRCRESAHA.120.317128

Source DB:  PubMed          Journal:  Circ Res        ISSN： 0009-7330            Impact factor:   17.367


× No keyword cloud information.
  19 in total

Review 1.  Cholesterol Lowering Biotechnological Strategies: From Monoclonal Antibodies to Antisense Therapies. A Pre-Clinical Perspective Review.

Authors:  S Bellosta; C Rossi; A S Alieva; A L Catapano; A Corsini; A Baragetti
Journal:  Cardiovasc Drugs Ther       Date:  2022-01-13       Impact factor: 3.727

Review 2.  Therapeutic RNA-silencing oligonucleotides in metabolic diseases.

Authors:  Algera Goga; Markus Stoffel
Journal:  Nat Rev Drug Discov       Date:  2022-02-24       Impact factor: 84.694

3.  High Density Lipoproteins: Is There a Comeback as a Therapeutic Target?

Authors:  Arnold von Eckardstein
Journal:  Handb Exp Pharmacol       Date:  2022

Review 4.  Recent Updates in Hypertriglyceridemia Management for Cardiovascular Disease Prevention.

Authors:  Renato Quispe; Ty Sweeney; Bhavya Varma; Anandita Agarwala; Erin D Michos
Journal:  Curr Atheroscler Rep       Date:  2022-07-27       Impact factor: 5.967

5.  A VLP-based vaccine targeting ANGPTL3 lowers plasma triglycerides in mice.

Authors:  Alexandra Fowler; Maureen Sampson; Alan T Remaley; Bryce Chackerian
Journal:  Vaccine       Date:  2021-08-30       Impact factor: 4.169

Review 6.  Potential of Phage Display Antibody Technology for Cardiovascular Disease Immunotherapy.

Authors:  Soo Ghee Yeoh; Jia Siang Sum; Jing Yi Lai; W Y Haniff W Isa; Theam Soon Lim
Journal:  J Cardiovasc Transl Res       Date:  2021-08-31       Impact factor: 3.216

7.  Identifying the Lipidomic Effects of a Rare Loss-of-Function Deletion in ANGPTL3.

Authors:  Laura F Michael; Joanne E Curran; Nicholas B Blackburn; Peter J Meikle; Juan M Peralta; Satish Kumar; Ana C Leandro; Melissa A Bellinger; Corey Giles; Kevin Huynh; Michael C Mahaney; Harald H H Göring; John L VandeBerg; Sarah Williams-Blangero; David C Glahn; Ravindranath Duggirala; John Blangero
Journal:  Circ Genom Precis Med       Date:  2021-04-22

8.  Genetic and Metabolic Determinants of Plasma Levels of ANGPTL8.

Authors:  Federico Oldoni; Kevin Bass; Julia Kozlitina; Hannah Hudson; Lisa M Shihanian; Viktoria Gusarova; Jonathan C Cohen; Helen H Hobbs
Journal:  J Clin Endocrinol Metab       Date:  2021-05-13       Impact factor: 5.958

Review 9.  Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8.

Authors:  Kelli L Sylvers-Davie; Brandon S J Davies
Journal:  Am J Physiol Endocrinol Metab       Date:  2021-08-02       Impact factor: 5.900

10.  ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia-Brief Report.

Authors:  Laurens F Reeskamp; John S Millar; Liya Wu; Hans Jansen; Dewi van Harskamp; Henk Schierbeek; Daniel A Gipe; Daniel J Rader; Geesje M Dallinga-Thie; G Kees Hovingh; Marina Cuchel
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-03-11       Impact factor: 8.311
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.